Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025GlobeNewsWire • 07/10/25
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome ConferenceGlobeNewsWire • 06/20/25
Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi SyndromeGlobeNewsWire • 05/22/25
Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi SyndromeGlobeNewsWire • 05/20/25
Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial ResultsGlobeNewsWire • 05/07/25
Soleno Therapeutics (SLNO) is on the Move, Here's Why the Trend Could be SustainableZacks Investment Research • 05/06/25
Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ETGlobeNewsWire • 04/23/25
Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, Pulling Aardvark HigherInvestors Business Daily • 03/27/25
Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic DisorderBenzinga • 03/27/25
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi SyndromeGlobeNewsWire • 03/26/25
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLCGlobeNewsWire • 12/17/24
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare ConferenceGlobeNewsWire • 11/27/24
Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi SyndromeGlobeNewsWire • 11/26/24
Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024GlobeNewsWire • 11/14/24
Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia TreatmentsSeeking Alpha • 10/10/24
Recent Price Trend in Soleno Therapeutics (SLNO) is Your Friend, Here's WhyZacks Investment Research • 10/09/24